<a href="https://www.fiercebiotech.com/biotech/busy-lilly-closes-202m-deal-preclinical-dna-delivery-biotech-engage" hreflang="en">Lilly pens $202M deal for preclinical DNA delivery biotech Engage as M&A streak continues</a>
Eli Lilly has acquired preclinical DNA delivery biotech Engage Biologics for $202 million as part of its ongoing strategy to expand through mergers and acquisitions. Engage's technology aims to improve DNA delivery systems, and the partnership is expected to accelerate the development of new genetic therapies.
Eli Lilly's acquisition of Engage Biologics for $202 million highlights the growing strategic focus on innovative DNA delivery platforms within biotech M&A. Engage's Tethosome platform, which aims to enhance DNA delivery via lipid nanoparticles and mRNA-encoded technologies, addresses key challenges in potency and redosability. For professionals in healthtech and biotech, this signals a potential investment opportunity in non-viral gene delivery systems that can overcome traditional limitations, aligning with broader trends in precision medicine and genetic therapies.